Brief: Elutia Signs Definitive Agreement To Sell Simpliderm® In Transaction Valued At Up To $11 Million, Strengthening Balance Sheet Ahead Of NXT-41X Launch
16/07/2026 22:45
BRIEF-Elutia Signs Definitive Agreement To Sell Simpliderm® In Transaction Valued At Up To $11 Million, Strengthening Balance Sheet Ahead Of NXT-41X Launch July 16 (Reuters) - Elutia Inc ELUT.O:
ELUTIA SIGNS DEFINITIVE AGREEMENT TO SELL SIMPLIDERM® IN TRANSACTION VALUED AT UP TO $11 MILLION, STRENGTHENING BALANCE SHEET AHEAD OF NXT-41X LAUNCH
ELUTIA - TO RECEIVE $8 MILLION CASH AT CLOSING, UP TO $3 MILLION IN MILESTONE PAYMENTS
ELUTIA - TO SELL SIMPLIDERM BUSINESS TO CELLUTION BIOLOGICS FOR UP TO $11 MILLION
Source text: ID:nGNXc56WMv
Further company coverage: ELUT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Elutia
See all newsBrief: Elutia Receives $8 Million Payment From Boston Scientific Company Now Fully Funded Into 2029
Elutia Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Elutia Secures $15 Million Loan Financing From Avenue Capital Group
Elutia's Q2 revenue falls on SimpliDerm production disruption
Elutia Inc expected to post a loss of 15 cents a share - Earnings Preview